← Back to the wire

Eli Lilly Drug Combo Leads to 23% Weight Loss in Diabetes Study

Product·3 articles across 3 outlets·↩ Updated

Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data

Eli Lilly & Co. announced that a new drug combination helped people with diabetes lose as much as 23% of their weight, more than other medicines in similar studies, suggesting it has the potential to be the drugmaker’s strongest obesity shot to date.

The investigational combination therapy, which includes Zepbound and an amylin drug, showed significant weight loss in a mid-stage study, but high discontinuation rates raised questions about tolerability.

Eli Lilly

Sources

Every quote below is verbatim from the article it is attributed to.

SourceReports the news
SupportCorroborates it

Earlier versions

  • Sep 30, 2:32 PM — Eli Lilly's Drug Combo Leads to 23% Weight Loss in Diabetes Study (3/3)
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.